Table 1 Clinicopathological characteristics of gastric cancer patients with or without TD before and after PSM
Factors | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
TD (-) % | TD (ā+) % | P | TD (-) % | TD (ā+) % | P | |
Gender | Ā | Ā | 0.641 | Ā | Ā | 1.000 |
āMale | 2154 (69.5) | 256 (70.7) | Ā | 249 (71.1) | 249 (71.1) | Ā |
āFemale | 944 (30.5) | 106 (29.3) | Ā | 249 (71.1) | 249 (71.1) | Ā |
Age | Ā | Ā | 0.011 | Ā | Ā | 0.545 |
āāā¤ā60Ā years | 1647 (53.2) | 167 (46.1) | Ā | 172 (49.1) | 164 (46.9) | Ā |
āā>ā60Ā years | 1451 (46.8) | 195 (53.9) | Ā | 178 (50.9) | 186 (53.1) | Ā |
Tumor location | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.583 |
āUpper | 611 (19.7) | 74 (20.4) | Ā | 58 (16.6) | 71 (20.3) | Ā |
āMiddle | 335 (10.8) | 38 (10.5) | Ā | 39 (11.1) | 37 (10.6) | Ā |
āLower | 1697 (54.8) | 164 (45.3) | Ā | 162 (46.3) | 161 (46.0) | Ā |
Two-thirds or more | 455 (14.7) | 86 (23.8) | Ā | 91 (26.0) | 81 (23.1) | Ā |
Type of gastrectomy | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.489 |
āDistal | 1927 (62.2) | 174 (48.1) | Ā | 185 (52.9) | 172 (49.1) | Ā |
āProximal | 383 (12.4) | 33 (9.1) | Ā | 139 (39.7) | 145 (41.4) | Ā |
āTotal | 788 (25.4) | 155 (42.8) | Ā | 26 (7.4) | 33 (9.5) | Ā |
Tumor size | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.437 |
āāā¤ā5Ā cm | 1561 (50.4) | 69 (19.1) | Ā | 61 (17.4) | 69 (19.7) | Ā |
āā>ā5Ā cm | 1537 (49.6) | 293 (80.9) | Ā | 289 (82.6) | 281 (80.3) | Ā |
Borrmann type | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.760 |
āIā+āII | 1957 (63.2) | 151 (41.7) | Ā | 152 (43.4) | 148 (42.3) | Ā |
āIIIā+āIV | 1141 (36.8) | 211 (58.3) | Ā | 198 (56.6) | 202 (57.7) | Ā |
Histologic type | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.126 |
āG1ā+āG2 | 813 (26.2) | 40 (11.0) | Ā | 28 (8.0) | 40 (11.4) | Ā |
āG3ā+āG4 | 2285 (73.8) | 322 (89.0) | Ā | 322 (92.0) | 310 (88.6) | Ā |
T stage | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.178 |
āT1 | 670 (21.6) | 1 (0.3) | Ā | 2 (0.6) | 1 (0.3) | Ā |
āT2 | 513 (16.6) | 16 (4.4) | Ā | 22 (6.3) | 16 (4.6) | Ā |
āT3 | 543 (17.5) | 74 (20.4) | Ā | 52 (14.9) | 74 (21.1) | Ā |
āT4a | 1187 (38.3) | 214 (59.1) | Ā | 231 (66.0) | 211 (60.3) | Ā |
āT4b | 185 (6.0) | 57 (15.7) | Ā | 43 (12.3) | 48 (13.7) | Ā |
N stage | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.794 |
āN0 | 1129 (36.4) | 14 (3.9) | Ā | 17 (4.9) | 14 (4.0) | Ā |
āN1 | 556 (17.9) | 40 (11.0) | Ā | 32 (9.1) | 40 (11.4) | Ā |
āN2 | 560 (18.1) | 73 (20.2) | Ā | 75 (21.4) | 73 (20.9) | Ā |
āN3a | 586 (18.9) | 146 (40.3) | Ā | 140 (40.0) | 145 (41.4) | Ā |
āN3b | 267 (8.6) | 89 (24.6) | Ā | 86 (24.6) | 78 (22.3) | Ā |
pTNM stage | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.993 |
āStage I | 818 (26.4) | 4 (1.1) | Ā | 3 (0.9) | 4 (1.1) | Ā |
āStage II | 797 (25.7) | 23 (6.4) | Ā | 25 (7.1) | 23 (6.6) | Ā |
āStage IIIA | 660 (21.3) | 99 (27.3) | Ā | 97 (27.7) | 99 (28.3) | Ā |
āStage IIIB | 498 (16.1) | 123 (34.0) | Ā | 124 (35.4) | 123 (35.1) | Ā |
āStage IIIC | 325 (10.5) | 113 (31.2) | Ā | 101 (28.9) | 101 (28.9) | Ā |
Perineural invasion | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.069 |
āAbsence | 2649 (85.5) | 269 (74.3) | Ā | 282 (80.6) | 262 (74.9) | Ā |
āPresence | 449 (14.5) | 93 (25.7) | Ā | 68 (19.4) | 88 (25.1) | Ā |
Lymphovascular invasion | Ā | Ā | ā<ā0.001 | Ā | Ā | 0.225 |
āAbsence | 2591 (83.6) | 232 (64.1) | Ā | 245 (70.0) | 230 (65.7) | Ā |
āPresence | 507 (16.4) | 130 (35.9) | Ā | 105 (30.0) | 120 (34.3) | Ā |
Chemotherapy | Ā | Ā | 0.453 | Ā | Ā | 0.430 |
āAbsence | 1996 (64.4) | 226 (62.4) | Ā | 230 (65.7) | 220 (62.9) | Ā |
āPresence | 1102 (35.6) | 136 (37.6) | Ā | 120 (34.3) | 130 (37.1) | Ā |